As we’ve learned what the acquisition of a portion of Ft. Dodge Animal Health means to Boehringer Ingelheim Vetmedica we’ve heard about cattle, hogs, dairy but how about dogs and cats? You’ll find many of them at your average farm of course. But this is a huge area for the animal health business.
According to Matt Musselman, Executive Director, Pet Division, BIVI, they now have the great opportunity to combine the chronic care pharmaceuticals they had with the vaccines they’ve acquired. He says, “As we look at the combination of that portfolio we really like the ability to surround the veterinarian and the pet owner with a set of products and services that allows them to care for that dog and cat throughout their life.” Looking forward he says that the strong bond people have with their pets and the desire to keep their pet healthy is something BIVI can help with by providing “Value Through Innovation.”
The big product story he says is their launch of PROZINC for the treatment of feline diabetes. He points to it as an example of the type of novel chronic care products we’ll see from BIVI in the future.
You can listen to my interview with Matt below.